


The Avellino SARS-CoV-2/COVID-19 Test (AvellinoCoV2) is a non-invasive, swab-based test used to detect the SARS-CoV-2 virus, a strong indicator of the patient having an active COVID-19 infection even before symptoms develop. Samples collected from the nose and throat are analyzed qualitatively and rapidly through reverse transcriptase Real-Time Polymerase Chain Reaction (rRT-PCR).




AvellinoCoV2 Kit Content		
Test Requisition Form	Sample Vial	
Instruction for Specimen Collection	Bio-Hazard Bag	
FLOQ Swabs (2)	Absorbent Pad	

CDC & FDA Recognized Targets	Specimen	Instrument Used in Lab
N Gene Target 1	Respiratory Specimen	Applied Biosystems 7500Fast (ThermoFisher)
N Gene Target 2	(Nasopharyngeal swab, and Oropharyngeal swab)	

## **Testing the Right Targets**

- (N) Nucleocapsid protein is a phosphoprotein that is complexed with genome RNA to form the nucleocapsid.
- N gene is highly conserved during mutation.
- (E) a membrane-spanning protein, is a minor component of the membrane.
- N gene targets are more sensitive due to high conservation during viral mutation.
   The E gene is a minor target which is difficult to detect and can lead to inconsistent test results.





### **Speed Matters**

- Avellino can analyze and deliver results of the AvellinoCoV2 test in just
   4 7 hours from time of receipt of the patient sample.
- Large-scale testing labs have represented their ability to turn-around tests in 2 to 3 days and are not expected to consistently report results in less than 12 hours.
- Our rapid and non-invasive test will allow you to screen and confirm
  the presence of the virus in your patients or employees early, thereby
  making it possible for you to make rapid workforce decisions on
  quarantining and other policies that will affect your operations.



# IS COVID-19 TESTING COVERED BY INSURANCE?

Under the Families First Coronavirus Response Act (Division G, Health Provisions) COVID-19 testing should be covered at no cost to the beneficiary/consumer

For detailed information on the Families First Coronavirus Response Act visit

https://www.congress.gov/bill/116th-congress/house-bill/6201

# HOW DO YOU BILL FOR TESTING?

#### **CPT Code:**

**87635\*\*** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease[COVID-19]), amplified probe technique.

\*\*CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

# HOW DO YOU CODE FOR TESTING?

### **Common Diagnosis Codes:**

- U07.1, COVID-19
- Z20.828, Contact with and (suspected) exposure to other viral communicable diseases
- Z03.818, Encounter for observation for suspected exposure to other biological agents ruled out
- Z11.59, Encounter for screening for other viral diseases
- J12.89, Other viral pneumonia
- J20.8, Acute bronchitis due to other specified organisms
- J40, Bronchitis not specified as acute or chronic
- J22, Unspecified acute lower respiratory infection
- J98.8, Other specified respiratory disorders
- J80, Acute respiratory distress syndrome
- R05, Cough
- R06.02, Shortness of breath
- R50.9, Fever, unspecified

For detailed information on ICD-10 official coding and reporting guidelines, visit:

https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf

# **About Avellino**

Avellino is a private molecular diagnostics company with expertise in PCR testing since 2012. In January 2020, Avellino started developing a new coronavirus test. As of March 2020, Avellino is a CLIA-Validated lab with FDA authorization under EUA2000006.

